AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
AbCellera (Nasdaq: ABCL) has announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, scheduled for November 6 to 10 at the George R. Brown Convention Center in Houston, Texas. The presentation, titled 'Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release', is assigned Abstract Number 1291 and will be displayed on Friday, November 8 from 9:00 a.m. to 7:00 p.m. CST. Attendees can view the poster in Exhibit Halls A B of the convention center or access it online at the SITC website.
AbCellera (Nasdaq: ABCL) ha annunciato una prossima presentazione di poster sulla sua piattaforma di engagers a cellule T durante il 39° Congresso Annuale SITC, che si svolgerà dal 6 al 10 novembre presso il George R. Brown Convention Center di Houston, Texas. La presentazione, intitolata 'Profilazione degli engagers bispecifici a cellule T: Strategie per migliorare la potenza riducendo al minimo il rilascio di citochine', ha ricevuto il numero di astrazione 1291 e sarà esposta venerdì 8 novembre dalle 9:00 alle 19:00 CST. I partecipanti potranno visionare il poster nelle Sale Espositive A e B del centro congressi o accederlo online sul sito web del SITC.
AbCellera (Nasdaq: ABCL) ha anunciado una próxima presentación de póster sobre su plataforma de engagers de células T en la 39ª Reunión Anual del SITC, programada del 6 al 10 de noviembre en el George R. Brown Convention Center en Houston, Texas. La presentación, titulada 'Perfilado de engagers bispecíficos de células T: Estrategias para aumentar la potencia mientras se minimiza la liberación de citoquinas', está asignada con el número de resumen 1291 y se exhibirá el viernes 8 de noviembre de 9:00 a.m. a 7:00 p.m. CST. Los asistentes pueden ver el póster en los Salones de Exposición A y B del centro de convenciones o acceder a él en línea a través del sitio web del SITC.
AbCellera (Nasdaq: ABCL)는 다가오는 T세포 결합제 플랫폼에 관한 포스터 발표를 SITC 제39차 연례 회의에서 발표한다고 발표했습니다. 이 회의는 텍사스 휴스턴에 있는 George R. Brown Convention Center에서 11월 6일부터 10일까지 열릴 예정입니다. '이중 특이적 T세포 결합제 프로파일링: 사이토카인 방출을 최소화하면서 효능을 향상시키는 전략'이라는 제목의 발표는 초록 번호 1291로 지정되어 있으며, 11월 8일 금요일 오전 9시부터 오후 7시까지 CST에 전시될 예정입니다. 참석자는 컨벤션 센터의 전시 홀 A와 B에서 포스터를 볼 수 있으며, SITC 웹사이트를 통해 온라인에서도 접근할 수 있습니다.
AbCellera (Nasdaq: ABCL) a annoncé une prochaine présentation d'affiche sur sa plateforme d'engagers de cellules T lors de la 39ème Réunion Annuelle du SITC, prévue du 6 au 10 novembre au George R. Brown Convention Center à Houston, Texas. La présentation, intitulée 'Profilage des engagers bispécifiques de cellules T : Stratégies pour améliorer la puissance tout en minimisant la libération de cytokines', est assignée au numéro d'abstract 1291 et sera affichée le vendredi 8 novembre de 9h00 à 19h00 CST. Les participants peuvent voir l'affiche dans les salles d'exposition A et B du centre de congrès ou y accéder en ligne sur le site Web du SITC.
AbCellera (Nasdaq: ABCL) hat eine bevorstehende Poster-Präsentation zu seiner T-Zell-Engager-Plattform auf dem 39. Jahresmeeting der SITC angekündigt, das vom 6. bis 10. November im George R. Brown Convention Center in Houston, Texas, stattfinden wird. Die Präsentation mit dem Titel 'Profilierung von bispezifischen T-Zell-Engagern: Strategien zur Verbesserung der Potenz bei gleichzeitiger Minimierung der Zytokinfreisetzung' trägt die Abstract-Nummer 1291 und wird am Freitag, den 8. November, von 9:00 bis 19:00 Uhr CST präsentiert. Teilnehmer können das Poster in den Ausstellungshallen A und B des Kongresszentrums einsehen oder online über die SITC-Website darauf zugreifen.
- AbCellera is presenting research on its T-cell engager platform at a major immunotherapy conference
- The presentation focuses on enhancing potency while minimizing cytokine release in bispecific T-cell engagers
- None.
Details on AbCellera’s poster presentation at SITC are as follows:
Title: Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release
Abstract Number: 1291
Date and Time: Friday, November 8 from 9:00 a.m. to 7:00 p.m. CST
Location: Exhibit Halls A B George R. Brown Convention Center or online at https://www.sitcancer.org/2024/home
About AbCellera’s T-Cell Engager Platform
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality, costimulatory building blocks to enhance efficacy for difficult-to-treat cancers, and discovery capabilities to broaden the range of T-cell engagers to complex peptide-MHC tumor targets. AbCellera is leveraging its platform to unlock the full potential of this modality and bring potential new cancer medicines to patients.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004724763/en/
Inquiries
Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116
Source: AbCellera Biologics Inc.
FAQ
What is AbCellera (ABCL) presenting at the SITC 39th Annual Meeting?
When and where is AbCellera's (ABCL) poster presentation at SITC 2024?
Can I view AbCellera's (ABCL) SITC 2024 poster presentation online?
What is the abstract number for AbCellera's (ABCL) SITC 2024 poster presentation?
